VEGF Gene Transfer for Critical Limb Ischemia

NCT00304837 | Completed Phase 1

• 1 other identifier: BB-IND 11948
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this gene therapy study is to evaluate the safety and efficacy of intramuscular gene transfer using Vascular Endothelial Growth Factor (VEGF) or placebo in patients with moderate to high-risk Critical Limb Ischemia (a condition in which there is poor blood circulation in the leg). This trial will assess whether VEGF improves rest pain and/or heals ulcers in the legs of patients with peripheral artery disease (blockages in leg arteries.) VEGF is DNA, or genetic material that will be injected into the leg muscles on three separate occasions, each 2 weeks apart. Once the DNA is in the leg, it directs the cells of the artery wall to increase its production of VEGF, which has been shown to cause new blood vessels to grow. This experimental therapy is designed to grow new blood vessels around blockages in the leg arteries. The total length of participation in this study is approximately 1 year and will require approximately 8 clinic visits within that year. Following enrollment in the study, testing may be done for cancer screening, blood work, physical exams, vascular testing and eye exams. There is no charge for any testing or office visits required by the study. This study has been approved by the Food and Drug Administration (FDA).

Conditions

Critical Limb Ischemia; Ischemia; Leg Ulcer

Keywords

Nonhealing leg ulcers; Ischemic rest pain

Interventions

pVGI.1 (VEGF-2) GENETIC

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be at least 21 years old
• Have critical limb ischemia
• Have severe blockages in at least one artery in the affected leg as demonstrated by an angiogram
• Have nonhealing leg ulcers and/ or have severe rest pain secondary to a severely decreased blood flow
• Agree to participate in follow-up.

You may not qualify if:

• Have any evidence of malignant neoplasms (other than non-melanoma skin cancer or in situ carcinoma) within the last 5 years
• Be pregnant or lactating
• Have a history of alcohol or drug abuse within 3 months of screening
• Have advanced (Rutherford Category 6) critical limb ischemia, characterized by extensive tissue loss or gangrene
• Have osteomyelitis
• Have undergone successful aortic or lower extremity surgery, angioplasty, or lumbar sympathectomy within the 2 months preceding screening
• Be a suitable candidate for surgical or endovascular revascularization in the limb in which treatment is proposed
• Subjects in whom arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder

Sponsors & Collaborators

• Losordo, Douglas, M.D.: lead

Study Sites (3)

Cardiology PC

Birmingham, Alabama, 35211, United States

Location

Caritas St. Elizabeth's Medical Center

Boston, Massachusetts, 02135, United States

Location

The Minneapolis Heart Institute at Abbott Northwestern Hospital

Minneapolis, Minnesota, 55407, United States

Location

MeSH Terms

Conditions

Chronic Limb-Threatening Ischemia; Ischemia; Leg Ulcer

Condition Hierarchy (Ancestors)

Peripheral Arterial Disease; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Peripheral Vascular Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Douglas W. Losordo, MD

  Northwestern University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Intervention Model: CROSSOVER
• Sponsor Type: INDIV

Study Record Dates

• First Submitted: March 16, 2006
• First Posted: March 20, 2006
• Study Completion: April 1, 2008
• Last Updated: October 19, 2010

Record last verified: 2008-04

Locations

US (3)